Glenn J. Lesser, MD
- Medical Oncology and Hematology
- Brain Tumor Specialty Team
Directions
Directions
Wake Forest Baptist Provider
Treats only Adults
In-person visits onlyAbout
Practicing Specialties
Languages
Conditions and Treatments
Ratings and Reviews
- Most Recent
- Highest Rating
- Lowest Rating
Locations
-
Atrium Health Wake Forest Baptist Hematology and Oncology - Cancer CenterWinston Salem, NC 27157Medical Center Boulevard3rd Floor
-
Atrium Health Wake Forest Baptist Comprehensive Cancer CenterWinston-Salem, NC 27157Medical Center Boulevard
Credentials
Board Certifications
Residencies
Fellowships
Memberships
Positions
Research Interests
Publications
Most Recent- Most Recent
- Alphabetical
- Oldest First
The Head and Neck Survivorship Tool (HN-STAR) Trial (WF-1805CD): A protocol for a cluster-randomized, hybrid effectiveness-implementation, pragmatic trial to improve the follow-up care of head and neck cancer survivors.
Salz T, Ostroff JS, Nightingale CL, Atkinson TM, Davidson EC, Jinna SR, Kriplani A, Lesser GJ, Lynch KA, Mayer DK, Oeffinger KC, Patil S, Salner AL, Weaver KE. Contemp Clin Trials. 2021 May; 107:106448.
Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood-Brain Barrier Permeability.
Molotkov A, Carberry P, Dolan MA, Joseph S, Idumonyi S, Oya S, Castrillon J, Konofagou EE, Doubrovin M, Lesser GJ, Zanderigo F, Mintz A. Pharmaceutics. 2021 Mar; 13(3)
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
Peereboom DM, Ye X, Mikkelsen T, Lesser GJ, Lieberman FS, Robins HI, Ahluwalia MS, Sloan AE, Grossman SA. Neurosurgery. 2021 01; 88(2):246-251.
Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors.
Ramkissoon LA, Pegram W, Haberberger J, Danziger N, Lesser G, Strowd R, Dahiya S, Cummings TJ, Bi WL, Abedalthagafi M, Sathyan P, McGregor K, Reddy P, Severson E, Williams E, Lin D, Edgerly C, Huang RSP, Hemmerich A, Creeden J, Brown C, Venstrom J, Hegde P, Ross JS, Alexander BM, Elvin J, Ramkissoon SH. Front Neurol. 2020; 11:544680.
Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.
Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'Agostino RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, Lesser GJ, Debinski W, Strowd RE. Sci Rep. 2020 09; 10(1):15195.
Capacity to Provide Geriatric Specialty Care for Older Adults in Community Oncology Practices.
Williams GR, Weaver KE, Lesser GJ, Dressler E, Winkfield KM, Neuman HB, Kazak AE, Carlos R, Gansauer LJ, Kamen CS, Unger JM, Mohile SG, Klepin HD. Oncologist. 2020 12; 25(12):1032-1038.
Efficacy of osimertinib against EGFRvIII+ glioblastoma.
Chagoya G, Kwatra SG, Nanni CW, Roberts CM, Phillips SM, Nullmeyergh S, Gilmore SP, Spasojevic I, Corcoran DL, Young CC, Ballman KV, Ramakrishna R, Cross DA, Markert JM, Lim M, Gilbert MR, Lesser GJ, Kwatra MM. Oncotarget. 2020 Jun; 11(22):2074-2082.
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Neuro Oncol. 2020 05; 22(5):601-612.
Way to Go/No-Go!.
Lesser GJ. Neuro Oncol. 2020 05; 22(5):596-597.
Esthesioneuroblastoma.
Klepin HD, McMullen KP, Lesser GJ. Curr Treat Options Oncol. 2005 Nov; 6(6):509-18.